Andrew P. Mazar
Co-Founder & COODr. Andrew P. Mazar, Ph.D., is the Founder and serves as Head of Product Development of Lung Therapeutics, Inc. He is the Co-Founder and serves as Chief Operating Officer of Actuate Therapeutics, Inc. since June 2022 and previously served as its Chief Scientific Advisor. Prior to joining the Company, he served as an independent consultant from January 2022 to June 2022. Dr. Mazar also co-founded Monopar Therapeutics Inc. and served as the Executive Vice President of Research and Development and Chief Scientific Officer since November 1, 2017 until April 8, 2022 and also had been its Director since December 2014 until April 8, 2022. Dr. Mazar is a veteran of drug discovery and development efforts and is internationally recognized for his basic research work on the role of the urokinase plasminogen activator (uPA) system in tumor progression and angiogenesis. He has founded or advised several start-up companies, including Tactic Pharma, Valence Therapeutics, Wilson Therapeutics, Panther Biotechnology, Lung Therapeutics Inc., Actuate Therapeutics, AvidTox and Tempus. Dr. Mazar established and directed all facets of pre-clinical research for Ångstrom Pharmaceuticals, Inc., where he was Vice President of Biology. He is the inventor of both the anti-angiogenic peptide 6, which was expected to enter Phase I clinical trials in 2002 and a novel uPA receptor-targeting peptide that was licensed to Diatide/Schering AG. Prior to joining Tactic Pharma in 2010 and the Chemistry of Life Processes Institute at Northwestern University in 2009, Dr. Mazar was the Chief Scientific Officer at Attenuon, LLC, a biopharmaceutical company in San Diego, from February 2000 to July 2009. Before Ångstrom, he worked at Abbott Laboratories, where he initiated two anti-angiogenesis pilot projects and was involved in the pre-clinical development of two biological agents that are in Phase III trials. He is also an Adjunct Professor of Medicine at the University of North Texas Health Science Center and an Advisory Board Member at the Institute for Cancer Research at that institution. Dr. Mazar serves as the Entrepreneur-in-Residence and the Director of the Center for Developmental Therapeutics (CDT) within the Chemistry of Life Processes Institute at Northwestern University. He is the Chair of the NCI Nano Alliance Animal Model working group and a Member of the NHLBI Scientific Review Board (SRB) for the SMARTT program, serves as Associate Editor for Recent Patent Reviews on Anti-Cancer Drug Discovery and is a Member of the editorial board of Clinical Cancer Research. He is the co-author of 99 peer-reviewed publications and 16 reviews and book chapters. Dr. Mazar has founded or advised several start-up companies and has been involved in raising investment and partnership capital for these entities. He is a frequent member of various oncology study sections. Dr. Mazar earned his BS in Chemistry from the University of Wisconsin, Parkside and his Ph.D. in Biochemistry from the University of Illinois College of Medicine, Chicago, Illinois.
公司職務
- 公司名稱Actuate Therapeutics, Inc.股票代碼ACTU職務Co-Founder & COO共事同僚
- DMDaniel M. SchmittCEO, President & Director
- AGAaron Glenn Louis FletcherIndependent Chairman
- PJPaul J. LytleChief Financial Officer
- AKAlan KozikowskiScientific Founder and Advisor
- DLDaniel L. ZabrowskiIndependent Director
- JAJason A. KeyesIndependent Director
- RBRoger B. CohenMember of Scientific Advisory Board
